Target intelligence / Profile preview

KAT8 regulatory NSL complex subunit 1 (KANSL1)

Target
KANSL1
Molecular classification
Chromatin-modifying protein, Scaffold protein (in multiprotein complexes), Histone modification (via complex involvement), Other (nuclear, non-enzymatic subunit)
01

Overview

KAT8 regulatory NSL complex subunit 1 (KANSL1) is a nuclear protein that functions as a core scaffolding component of the evolutionarily conserved nonspecific lethal (NSL) complex, a multiprotein assembly crucial for chromatin-based transcriptional regulation and cell division[3][5][8]. The NSL complex, which includes the histone acetyltransferase MOF (KAT8), is responsible for acetylating lysine residues (notably Lys-16 and Lys-5) on histone H4, promoting transcriptionally active chromatin and the priming of developmental genes[1][4]. KANSL1 is predicted to be intrinsically disordered and mediates interactions among NSL complex subunits, playing a central role as a scaffold to recruit and organize the complex on chromatin targets[5][9]. During mitosis, KANSL1 relocates to the mitotic spindle, stabilizing microtubule minus ends and ensuring proper chromosome segregation[1][3]. Loss of function or deletion of KANSL1 causes Koolen-de Vries syndrome, characterized by developmental delay, intellectual disability, congenital organ anomalies, and distinctive facial features[2][7]. Although alterations in its expression and function are linked to disease states, KANSL1 itself is not a direct drug target, nor are there presently drugs or small molecule modulators specifically interacting with it.

Other names
CENP-36KIAA1267MSL1V1NSL1hMSL1v1DKFZP727C091MSL1v1KDVSMLL1/MLL complex subunit KANSL1MSL1 homolog 1NSL complex protein NSL1Non-specific lethal 1 homologcentromere protein 36C17DELq21.31DEL17Q21.31
02

Biological functions

Chromatin-based transcription regulationAcetylation of histone H4 (via NSL complex)Regulation of gene expressionSpindle assembly and chromosome segregation during mitosisMaintenance of cell proliferation and development
03

Disease associations

Koolen-de Vries syndrome (monogenic neurodevelopmental disorder)Potential roles in cancer (misregulation reported, but no direct disease-targeting therapies established)Other neurodevelopmental disorders (indirect evidence)
04

Safety considerations

Haploinsufficiency (loss-of-function, as in deletions/mutations) results in neurodevelopmental deficits and multisystem developmental anomalies (Koolen-de Vries syndrome)[2][7]No notable safety issues for direct targeting, as it is not a current therapeutic target
05

Biomarkers

Deletion or mutation of KANSL1 as a diagnostic marker for Koolen-de Vries syndrome[2][7]

Beyond the preview

Go deeper on KAT8 regulatory NSL complex subunit 1 (KANSL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAT8 regulatory NSL complex subunit 1 (KANSL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call